2Flo Ventures Welcomes Esteemed Pharmaceutical Executive Rodney Cotton, MBA, MSSM as a Venture PartnerCHICAGO, December 4, 2024-- 2Flo Ventures, a burgeoning venture capital firm and startup studio dedicated to the discovery, development, and commercialization of healthcare solutions aimed at addressing health disparities and promoting health equity, proudly announces the addition of Rod Cotton as a Venture Partner..

2Flo Ventures欢迎尊敬的制药高管Rodney Cotton，MBA，MSSM作为风险合作伙伴芝加哥，2024年12月4日——2Flo Ventures是一家新兴的风险投资公司和创业工作室，致力于发现、开发和商业化旨在解决健康差距和促进健康公平的医疗保健解决方案，骄傲地宣布加入Rod Cotton作为风险合作伙伴。。

Mr. Cotton brings more than four decades of extensive experience in the pharmaceutical industry, having led commercial and sales operations for various medicines and diagnostics. His illustrious career includes leadership roles at GlaxoSmithKline, Baxter International, and most recently, Roche, where he served as Senior Vice President, Chief of Staff to the CEO of Diagnostics, and Head of Strategy & Transformation.

科顿先生在制药行业拥有40多年的丰富经验，曾领导过各种药物和诊断的商业和销售业务。他杰出的职业生涯包括在葛兰素史克（GlaxoSmithKline）、百特国际（Baxter International）以及最近在罗氏（Roche）担任领导职务，在罗氏担任高级副总裁、诊断首席执行官办公室主任以及战略与转型主管。

Mr. Cotton also serves on the boards of Castle Biosciences, Eisai Pharmaceutical U.S. (subsidiary of Eisai Co., Ltd), Moleculera Biosciences, Orchard Software, and Community Health Network..

。。

Cotton is renowned in the pharmaceutical industry for his holistic perspective, proactive approach to challenges, and commitment to agile processes. At Roche, he spearheaded key enterprise initiatives, including milestone corporate communications, health equity coalitions, the U.S./Roche Group audit, and global/U.S.

Cotton以其整体观点、积极应对挑战的方法以及对敏捷流程的承诺而在制药行业享有盛誉。在罗氏，他领导了关键的企业计划，包括里程碑式的企业沟通、健康权益联盟、美国/罗氏集团审计和全球/美国。

acquisition integrations. With over 40 years of experience, Cotton has driven the financial turnaround and cultural transformation of four global healthcare companies, led teams of up to 280 members, managed a P&L exceeding $1 billion in revenue, and played a pivotal role in the most significant restructuring of the company in two decades..

收购整合。。。

Paul Burton, JD, MBA, Managing Partner at 2Flo, commented: 'This is an exciting moment in 2Flo's growth. Rod's addition to the team further strengthens our network and knowledgebase. As part of our mission as investors in areas of high unmet need, we are proud to support companies through significant milestones, including the current Phase III trial for Vivacelle Bio's treatment for hypovolemia in septic shock.

2Flo管理合伙人、法学博士、MBA保罗·伯顿（PaulBurton）评论道：“这是2Flo发展中令人兴奋的时刻。Rod加入团队进一步加强了我们的网络和知识库。作为我们在未满足需求的领域作为投资者的使命的一部分，我们很自豪能够通过重大里程碑支持公司，包括目前Vivacelle Bio治疗败血性休克低血容量的III期试验。

With Rod's expertise and the extensive experience of our 40+ advisors, we believe we can further leverage our platform's strengths to benefit both current and prospective portfolio companies, with the goal of generating meaningful returns for our stakeholders.'.

凭借罗德的专业知识和40多名顾问的丰富经验，我们相信我们可以进一步利用我们平台的优势，使当前和未来的投资组合公司受益，目标是为我们的利益相关者创造有意义的回报。”。

During the COVID-19 pandemic, Cotton and his team at Roche accelerated the development of six groundbreaking products in just 11 months, including the launch of the market's most accurate and in-demand molecular diagnostic test. He also tackled challenges related to product scarcity, supply chain, product allocation, and logistics to achieve accelerated global sourcing and self-manufacturing in alignment with testing guidelines.

在新型冠状病毒（COVID-19）大流行期间，科顿（Cotton）和他在罗氏（Roche）的团队在短短11个月内加速了六种开创性产品的开发，包括推出了市场上最准确和最受欢迎的分子诊断测试。他还应对了与产品稀缺性、供应链、产品分配和物流相关的挑战，以根据测试指南加速全球采购和自主制造。

For his exceptional contributions, he received The Sagamore of the Wabash Award, one of Indiana's highest honors, from Governor Eric J. Holcomb..

由于他的杰出贡献，他获得了印第安纳州州长埃里克·霍尔科姆颁发的瓦巴什奖（Wabash Award）的萨加摩尔奖（Sagamore of The Wabash Award），这是印第安纳州的最高荣誉之一。。

Cotton holds an MBA from California State University, Dominguez Hills, an M.S. in Strategic Management from the University of Southern California, and a B.A. in Biological Sciences & Technology from the University of California at Santa Barbara.

Cotton拥有加利福尼亚州立大学Dominguez Hills的MBA学位，南加州大学战略管理硕士学位，以及加利福尼亚大学圣巴巴拉分校的生物科学与技术学士学位。

Mr. Cotton's diverse expertise in therapeutics, diagnostics, and devices makes him a valuable addition to both our investment and startup studio teams. Regarding his new role, Cotton remarked, 'I am honored to join such a dynamic and forward-thinking team at 2Flo Ventures. With a strong commitment to driving advancements in healthcare, I am eager to leverage my experience in strategic planning and execution to fuel growth and success for our portfolio companies.

科顿先生在治疗、诊断和设备方面的丰富专业知识使他成为我们投资和创业工作室团队的宝贵补充。关于他的新角色，科顿说：“我很荣幸加入2Flo Ventures这样一个充满活力和前瞻性思维的团队。凭借对推动医疗保健进步的坚定承诺，我渴望利用我在战略规划和执行方面的经验，推动我们投资组合公司的增长和成功。

Together, with urgency and determination, I am confident we can navigate the challenges and seize the opportunities ahead, accelerating innovation and creating meaningful impact. I am ready to embark on this exciting journey of transformation and progress with such a special team.'.

我相信，在紧迫感和决心的帮助下，我们能够应对挑战，抓住未来的机遇，加速创新，产生有意义的影响。我准备与这样一支特殊的团队一起踏上这段激动人心的变革和进步之旅。”。

Cuthbert Simpkins, MD, Chief Innovation Officer of Vivacelle Bio, added: 'I am honored to have initially worked alongside Rod during his previous advisory role with the 2Flo team. In a short time, he helped us develop commercial strategies that will ensure access to our products through hospitals globally.

Vivacelle Bio首席创新官、医学博士Cuthbert Simpkins补充道：“我很荣幸能在Rod之前担任2Flo团队顾问期间与他一起工作。在很短的时间内，他帮助我们制定了商业战略，以确保通过全球医院获得我们的产品。

Looking ahead, we are excited to have him as a full resource through 2Flo's unique venture studio model. We believe Rod and the entire 2Flo team fully embrace and work towards securing health equity and access for all. We are proud to be part of their ecosystem and to propel their mission forward.'.

展望未来，我们很高兴能通过2Flo独特的风险投资工作室模式让他成为我们的全部资源。我们相信Rod和整个2Flo团队完全接受并致力于确保所有人的健康公平和机会。我们很自豪成为他们生态系统的一部分，并推动他们的使命向前发展。”。

The 2Flo team is supported by an extensive cohort of advisors with deep life sciences experience.

2Flo团队得到了一大批具有丰富生命科学经验的顾问的支持。

About 2Flo Ventures

关于2Flo Ventures

2Flo Ventures is a Chicago based early-stage venture capital firm and startup studio. We have invested in nine nationally recognized companies employing 100+ people and have collectively raised over 85 million dollars. We build and invest in companies across biotechnology, medical devices, and digital health with a core mission of advancing health equity and addressing large unmet medical needs.

2Flo Ventures是一家总部位于芝加哥的早期风险投资公司和创业工作室。我们投资了9家拥有100多人的国家认可公司，共筹集了8500多万美元。我们建立并投资于生物技术、医疗器械和数字健康领域的公司，其核心使命是促进健康公平并解决大量未满足的医疗需求。

For more information, please visit www.2floventures.com.Contact: .

有关更多信息，请访问www.2floventures.com.Contact：。。

Media Relations

媒体关系

Tiberend Strategic Advisors, Inc.

西藏战略顾问公司。

Casey McDonald

凯西·麦克唐纳

(646) 577-8520

(646) 577-8520

cmcdonald@tiberend.com

cmcdonald@tiberend.com